CCO Infectious Disease Podcast
Weekly updates on new data and best practices in patient care for a variety of infectious diseases including COVID-19, HIV, and viral hepatitis, from Clinical Care Options. Gain practical strategies and earn CME/CE credit for selected episodes.
- Update frequency
- every 3 days
- Average duration
- 25 minutes
- Episodes
- 461
- Years Active
- 2020 - 2025
COVID-19: Which Drug, When, and Why? Antiviral Agents
Antiviral agents continue to be effective against different strains of SARS-CoV-2 when used early in the disease course. In this episode, learn about the role of antiviral agents in hospitalized and …
COVID-19: Which Drug, When, and Why? Monoclonal Antibody Treatments
The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatme…
How Stigma and Socioeconomic Barriers Impede HCV Care: Conversations Between Patient and Physician
In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and a patient with previous injection drug use who has been cured of HCV infection discuss critical barriers that are preventing more people with …
Long COVID
In this episode, Renslow Sherer, MD, discusses what is known to date regarding long COVID, also known as postacute sequelae of COVID-19 infection, including:
- Possible causes and risk factors
- Signs and …
Importance of Screening for HCC in HBV: Patient and Physician Sharing Session #7
In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss:
- Role of family history in risk of…
COVID-19: Which Drug, When, and Why? Anti-inflammatory Agents and Immunomodulators
Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.
In this episode, Vikramjit Mukherjee, MD, discusse…
Key Decisions in HIV Care: Managing ART With Opportunistic Infections
In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, inclu…
Hepatitis Delta a Major Global Problem: Screening, Diagnosis, and Treatment in 2022 – Physician Discussion #1
In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disea…
The Ups and Downs of Living With HBV: Conversations Between Patient and Physician #4
Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in r…
Key Decisions in HIV Care: PrEP Considerations in Cisgender Men and Transgender Women
In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, i…
Key Decisions in HIV Care: PrEP Considerations in Cisgender Women
In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including:
- Discussion…
Lessons From Lockdown: HCC and Liver Transplant Care in the COVID-19 Era
In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including:
• Global impact of HCC and stra…
Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP
In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).
- Listen as he gives his perspectives on:
- The FDA appro…
Rational Use of New and Emerging Agents for Hepatitis Delta Virus
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner We…
Conference Conversations: HIV Advanced Practice Provider Perspectives from CROI 2022
In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including:
- Perinatal antiretroviral therapy exposure
- Inves…
Conference Conversations: HIV Pharmacist Perspectives from CROI 2022
In this episode, Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, share insights on new HIV data from CROI 2022, including:
- Islatravir tissue and plasma distribution after monthly oral dosing
- Ph…
HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy
In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:
- Epidemiology and burden of nosocomial bacterial p…
Lessons From Lockdown: Viral Hepatitis Testing and Treatment in the COVID-19 Era—Audio Recap
In this episode, Jordan J. Feld, MD, MPH, and Nancy Reau, MD, share lessons learned in the testing and treatment of viral hepatitis in the COVID-19 era, including:
- Global impact of the COVID-19 pandem…
Key HIV Studies Influencing My Practice Following CROI 2022—Audio Recap
In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:
- Prevention strategies
- LA therapies
- Second-line therapies
- The VISEND study comparing dolute…
Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP
In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).
Listen as he gives his perspectives on the:
- PrEP pipeline and the importance o…